Compare Repligen Corporation Common Stock (RGEN) vs SkyWest Inc (SKYW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs SkyWest Inc — how do they compare? Repligen Corporation Common Stock trades at $178.85 (market cap $11.31B), while SkyWest Inc trades at $90.69 (market cap $3.59B). The key difference: Repligen Corporation Common Stock is far larger — about 3.2× SkyWest Inc's market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, SkyWest Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and SkyWest Inc for 8 Days on average.
| RGEN | SKYW | |
|---|---|---|
Market Cap | $11.31B | $3.59B |
Volume | 1,216,919 | 419,815 |
Sector | Health | Industrials |
52-Week High | $194.57 | $115.94 |
52-Week Low | $102.87 | $78.40 |
Typical Hold Time | 0 Days | 8 Days |
Enterprise Value | $11.20B | $5.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
SkyWest (SKYW) trades at $94.52, down 0.53% with a bearish technical signal despite positive analyst sentiment. The stock shows mixed earnings performance with a recent Q1 2026 beat but Q2 2026 miss, while maintaining solid fundamentals including a 9.78% net income margin and attractive valuation at 9.39 P/E. Recent news highlights fleet modernization efforts and expanding flying agreements as growth catalysts amid cost pressures.
The stock presents a compelling value opportunity with 58.8% analyst buy ratings and $112 consensus target, offering 18.5% upside potential. However, technical weakness and executive stock sales create near-term headwinds. Long-term prospects remain positive driven by operational improvements and strategic partnerships, though investors should monitor cost management and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About SkyWest Inc
SkyWest, Inc. is a major North American regional airline company, operating primarily through its subsidiary, SkyWest Airlines. The company provides regional airline service to various large airlines under contract, including United Airlines (as United Express), Delta Air Lines (as Delta Connection), American Airlines (as American Eagle), and Alaska Airlines (as Alaska SkyWest). SKYW's primary business is providing essential flight services, connecting smaller cities to major airline hubs across the United States.
Read more on SKYW →
